Chimeric Therapeutics Limited

As of June 30, 2025, Chimeric Therapeutics Limited carries a market capitalization of 8.06M, placing it among publicly traded companies globally. Its enterprise value stands at 2.30M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Chimeric Therapeutics Limited's next confirmed earnings release is scheduled for February 26, 2027.

As of June 30, 2025, Chimeric Therapeutics Limited has 20.15M shares outstanding.

These figures are as of June 30, 2025. The price-to-sales ratio is 1.36, and the price-to-book ratio stands at 4.08.

These figures are as of June 30, 2025. The EV/Sales ratio of 0.58 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.30M versus a market cap of 8.06M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2025, Chimeric Therapeutics Limited maintains a current ratio of 0.72, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2025, Chimeric Therapeutics Limited posted a negative return on equity (ROE) of -469.35, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -56.62, reflecting losses generated across the asset base.

Over the twelve months ended June 30, 2025, Chimeric Therapeutics Limited recorded 110,809.00 in income tax expense. The company reported a pretax loss of -10.32M and -10.43M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on September 30, 2026, Chimeric Therapeutics Limited's stock has declined approximately 99.00% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.14.

Over the twelve months ended June 30, 2025, Chimeric Therapeutics Limited generated 3.97M in revenue and converted that into -10.43M in net income, yielding earnings per share of -0.77. EBITDA reached -14.08M, while operating income came in at -15.11M.

These figures are as of June 30, 2025. Total book value stands at 1.97M, with working capital of -4.09M providing operational flexibility.

Over the twelve months ended June 30, 2025, Chimeric Therapeutics Limited posted a gross margin of 78.66, reflecting its pricing power and cost economics. The operating margin of -380.78 and net profit margin of -262.83 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Total shareholder yield is negative at -124.63, meaning Chimeric Therapeutics Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Chimeric Therapeutics Limited's most recent stock split took place on May 1, 2026 with a 100:1 split ratio.

As of June 30, 2025, Chimeric Therapeutics Limited has an Altman Z-Score of -14.73, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.